ABVX:EPA
Abivax SA
€ ७६.१०
arrow_downward
-०.७२%(-०.५५) 1D
नोभेम्बर १९, १७:३५:२६ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€ ७७.३५
High
€ ७९.३०
Low
€ ७५.८५
Mkt. cap
६.६९ अरब
Avg. vol.
१.१० लाख
Volume
०.००
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
Open
€ ७७.३५
High
€ ७९.३०
Low
€ ७५.८५
Mkt. cap
६.६९ अरब
Avg. vol.
१.१० लाख
Volume
०.००
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
News stories
From web sources and news partners
Benzinga
·
५९ मिनेट पहिले
Stock Market: Will S&P 500 Open Up or Down Today?
FOREX.com
·
१ घण्टा पहिले
S&P 500 Analysis: SPX Is Going Through One of Its Most Difficult Periods of 2026
Adam Feldman | Substack
·
१२ घण्टा पहिले
Inside the Federal Litigation of Five S&P 500 Giants
BigGo Finance
·
६ घण्टा पहिले
Chip ETF Eyes Unprecedented Fourth Straight Year of Beating the S&P 500
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees९८
Founded२०१३ डिसेम्बर ४
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com